Literature DB >> 6423093

Treatment of hypercalcaemia associated with malignancy.

R Wilkinson.   

Abstract

Entities:  

Mesh：

Year:  1984        PMID： 6423093      PMCID： PMC1441596          DOI： 10.1136/bmj.288.6420.812

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  21 in total

1.  Effect of glucocorticoids on bone resorption in tissue culture.

Authors:  L G Raisz; C L Trummel; J A Wener; H Simmons
Journal:  Endocrinology       Date:  1972-04       Impact factor: 4.736

2.  Failure of corticosteroid therapy to correct the hypercalcaemia of malignant disease.

Authors:  N C Thalassinos; G F Joplin
Journal:  Lancet       Date:  1970-09-12       Impact factor: 79.321

Review 3.  Drugs for disorders of bone: pharmacological and clinical considerations.

Authors:  G R Mundy; L G Raisz
Journal:  Drugs       Date:  1974       Impact factor: 9.546

4.  New approach to the treatment of hypercalcemia. The effect of short-term treatment with mithramycin.

Authors:  R E Slayton; B I Shnider; E Elias; J Horton; C P Perlia
Journal:  Clin Pharmacol Ther       Date:  1971 Sep-Oct       Impact factor: 6.875

5.  Mithramycin treatment of hypercalcemia.

Authors:  C P Perlia; N J Gubisch; J Wolter; D Edelberg; M M Dederick; S G Taylor
Journal:  Cancer       Date:  1970-02       Impact factor: 6.860

6.  Acute treatment of hypercalcemia with furosemide.

Authors:  W N Suki; J J Yium; M Von Minden; C Saller-Hebert; G Eknoyan; M Martinez-Maldonado
Journal:  N Engl J Med       Date:  1970-10-15       Impact factor: 91.245

7.  Effects of glucocorticoids on osteoclast-activating factor.

Authors:  M Strumpf; M A Kowalski; G R Mundy
Journal:  J Lab Clin Med       Date:  1978-11

8.  Mechanism of the hypocalcemic effect of mithramycin.

Authors:  D T Kiang; M K Loken; B J Kennedy
Journal:  J Clin Endocrinol Metab       Date:  1979-02       Impact factor: 5.958

9.  Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  F J van Breukelen; O L Bijvoet; A T van Oosterom
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

10.  Calcium metabolism in cancer. Studies using calcium isotopes and immunoassays for parathyroid hormone and calcitonin.

Authors:  R S Coombes; M K Ward; P B Greenberg; C J Hillyard; B R Tulloch; R Morrison; G F Joplin
Journal:  Cancer       Date:  1976-11       Impact factor: 6.860
View more
  7 in total

Review 1.  Palliative medicine.

Authors:  R J George; A L Jennings
Journal:  Postgrad Med J       Date:  1993-06       Impact factor: 2.401

2.  Potentiation of calcitonin by corticosteroids during the treatment of the hypercalcaemia of malignancy.

Authors:  D J Hosking; M D Stone; J W Foote
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

4.  Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer.

Authors:  B M Cantwell; A L Harris
Journal:  Br Med J (Clin Res Ed)       Date:  1987-02-21

Review 5.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

6.  Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation.

Authors:  S Takahashi; S Goldring; M Katz; S Hilsenbeck; R Williams; G D Roodman
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

7.  Treatment of malignant hypercalcaemia with clodronate.

Authors:  R C Percival; A D Paterson; A J Yates; D J Beard; D L Douglas; F E Neal; R G Russell; J A Kanis
Journal:  Br J Cancer       Date:  1985-05       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.